trending Market Intelligence /marketintelligence/en/news-insights/trending/KWsTeCgtC_ptW-CZ6pXpfg2 content esgSubNav
In This List

Sinovac seeks China FDA approval for pneumonia vaccine

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Sinovac seeks China FDA approval for pneumonia vaccine

Sinovac Biotech Ltd. filed an application seeking approval for its lung infection vaccine from the China Food and Drug Administration.

The vaccine will be used to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia, among adults aged 65 or older and children older than two years with serious long-term health problems.

The submission is supported by a phase 3 clinical trial.